Bruker stock price target lowered to $40 by TD Cowen on weak demand

Bruker (NASDAQ:BRKR) reported weaker-than-expected Q2 2025 earnings and revenue, prompting a reduction in its 2025 guidance and a 9% stock decline, pushing it near its 52-week low. This performance led TD Cowen to lower its price target to $40 from $47, maintaining a Hold rating, with other firms like Stifel, JPMorgan, and Barclays also adjusting their targets downward. Management is implementing "significant cost actions" to protect 2026 EPS amid a "weak" demand environment with "low visibility," though some analysts note continued investor interest in a potential demand bottom.

Analysis

Bruker Corporation (BRKR) is facing significant operational and market pressure following a Q2 2025 earnings report that missed analyst expectations. The company reported an EPS of $0.32, a 23.81% shortfall against the $0.42 forecast, and revenue of $797.4 million, which was 1.9% below consensus. This underperformance prompted management to reduce its 2025 guidance, leading to a sharp negative market reaction, with the stock falling 9% on the day of the announcement and 17.44% over the past week to trade near its 52-week low. The negative sentiment is amplified by seven analysts revising earnings expectations downward and a series of price target cuts from firms including TD Cowen (to $40), Stifel (to $40), JPMorgan (to $50), and Barclays (to $43). In response to what TD Cowen describes as a "weak" demand environment with "low visibility," Bruker's management is implementing "significant cost actions" to protect its 2026 EPS. Despite the broad-based target reductions and a high P/E ratio of 63.35x, some analysts at JPMorgan and Barclays have maintained their "Overweight" ratings, and TD Cowen notes that investor interest remains high, suggesting a segment of the market may be anticipating that demand is nearing a cyclical bottom.

Key Decisions for Investors

• Given the substantial earnings miss, reduced 2025 guidance, and a wave of downward analyst revisions, investors should view Bruker with caution, monitoring for signs of demand stabilization and the effectiveness of management's cost-cutting initiatives.
• The stock's elevated P/E ratio of 63.35x appears inconsistent with the current weak fundamentals and low visibility, suggesting the valuation may not fully reflect the near-term operational risks.
• For long-term investors with a higher risk tolerance, the stock's proximity to its 52-week low and the maintained Overweight ratings from some analysts could signal a potential entry point, but this is contingent on the company successfully navigating the current challenging environment and achieving its 2026 earnings protection goals.